7 completed, 3 terminated, 1 recruiting. 11 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 7, Terminated 3, Recruiting 1 |
Follow Healthy Controls: new trials by email Literature Review of Healthy Controls trials Research Report on Healthy Controls
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers Placebo pills for 14-day intervention, VVZ-2471 for 14-day intervention - Healthy Controls | Phase 1 | Recruiting | Virginia Commonwealth University | 60 | 2026-08-28 | 2026-09-01 |
| Identification of a Safe and Non-Psychedelic Dose of Psilocybin Psilocybin (low dose) or Placebo - Healthy Controls | Phase 1 | Completed | Diamond Therapeutics Inc. | 56 | 2021-10-19 | 2026-07-17 |
| Intranasal Insulin and Olanzapine Study in Healthy Volunteers OLANZapine 2.5 MG, Placebo, Insulin Lispro 100 UNT/ML - Healthy Controls | Phase 1 | Completed | Centre for Addiction and Mental Health | 46 | 2019-10-22 | 2026-10-19 |
| Reliability of [18F]-FTC-146 Brain Uptake in Healthy Controls [18F]-FTC-146 - Healthy Controls | Phase 1 | Completed | Stanford University | 5 | 2019-02-01 | 2026-08-13 |
| [11C]Yohimbine PET Study of alpha2-AR [11C]Yohimbine, [11C]Yohimbine (Part B1) and [11C]Yohimbine + clonidine (Part B2) - Healthy Controls | Phase 1 | Completed | Hospices Civils de Lyon | 16 | 2018-05-21 | 2025-09-12 |
| Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder 4 mg Delta-9-THC, Placebo, 2 mg Delta-9-THC - Delta-9-Tetrahydroncannabinol, Bipolar Disorder | Phase 1 | Terminated | Yale University | 2 | 2017-08-01 | 2022-01-31 |
| Pomaglumetad Effects on Glutamate Biomarkers POMA, placebo - Healthy Controls | Phase 1 | Completed | New York State Psychiatric Institute | 95 | 2016-10-01 | 2018-09-12 |
| The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23 Atorvastatin, Pneumovax 23, Placebo (lactose pill) - Healthy Controls | Phase 1 | Completed | University of Florida | 33 | 2014-06-01 | 2015-09-28 |
| Peripheral Metabolic Effects of Ghrelin Ghrelin - Healthy Controls | Phase 1 | Completed | University of Aarhus | 8 | 2008-10-01 | 2009-02-03 |
| Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects [123I]CLINDE - Parkinson Disease, Alzheimer Disease | Phase 1 | Terminated | Institute for Neurodegenerative Disorders | 46 | 2008-01-01 | 2019-04-03 |
| Response of Airway Cells to 20,000 EU of Endotoxin in Normal Adults Clinical Center Reference Endotoxin (CCRE) - Healthy Controls | Phase 1 | Terminated | University of North Carolina, Chapel Hill | 26 | 2003-08-01 | 2012-10-08 |
Alzheimer Disease (1) · Anxiety Disorders (1) · Bipolar Disorder (1) · Multiple Sclerosis (1) · Parkinson Disease (1)
Mental Disorders (3) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Basal Ganglia Diseases (1) · Bipolar and Related Disorders (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Dementia (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Immune System Diseases (1) · Mood Disorders (1) · Movement Disorders (1) · Nervous System Diseases (1) · Neurocognitive Disorders (1)
23-valent pneumococcal capsular polysaccharide vaccine (1) · 6-(3-fluoropropyl)-3-(2-(azepan-1-yl)ethyl)benzo(d)thiazol-2(3H)-one (1) · 6-chloro-2-(4'-iodophenyl)-3-(N,N-diethyl)imidazo(1,2-a)pyridine-3-acetamide (1) · Atorvastatin (1) · Clonidine (1) · Dronabinol (1) · Ghrelin (1) · Lactose (1) · Methods (1) · Olanzapine (1) · Psilocybin (1) · Sodium Chloride (1) · poly(n-octyl methacrylate) (1) · pomaglumetad methionil (1)
Centre for Addiction and Mental Health (1) · Diamond Therapeutics Inc. (1) · Hospices Civils de Lyon (1) · Institute for Neurodegenerative Disorders (1) · New York State Psychiatric Institute (1) · Stanford University (1) · University of Aarhus (1) · University of Florida (1) · University of North Carolina, Chapel Hill (1) · Virginia Commonwealth University (1) · Yale University (1)
United States (7) · Canada (2) · Denmark (1) · France (1)
Carolyn Rodriguez, MD, PhD (1) · Danna L Jennings, M.D. (1) · David B Peden, MD, MS (1) · Esben T Vestergaard, PhD (1) · F. Gerard Moeller, MD (1) · Jeffrey A Lieberman, MD (1) · Jens Otto L. Jorgensen, MD (1) · Margaret K Hahn, PhD, MD (1) · Mark L Brantly, MD (1) · Mohini Ranganathan, MD (1) · Satya Dash, MD, PhD (1)
PMID 30686636, PMID 36441736, PMID 37238713, PMID 42797541
1RC1ES018417 (1), 1UG3DA063353 (1), 2018 (1), 271201200007I-4-27100003-2 (1)